Total revenues were $14.6 million for the year ended December 31, 2007, compared to total revenues of $11.3 million for the year ended December 31, 2006. Net loss for the fourth quarter of 2007 was $2.7 million, or $0.11 per basic and diluted share, compared to a net loss of $5.9 million, or $0.44 per share in the corresponding period in 2006.
Net loss for the year ended December 31, 2007 was $18.3 million, or $0.87 per basic and diluted loss per share compared to a net loss of $23.5 million, or $1.75 per share in the year ended December 31, 2006.
Timothy Walbert, president and CEO of IDM Pharma, said: “We are developing L-MTP-PE for the treatment of osteosarcoma, the most common type of bone cancer affecting adolescents. We remain committed to resolving the remaining items of the L-MTP-PE European marketing authorization application and working at the same time to advance this important potential treatment through its US regulatory path.”